ClinicalTrials.gg
CompletedNCT02259855Updated Jan 22, 2025

Pharmacokinetics (PK) of Tipranavir/Ritonavir, Ribavirin, Pegylated Interferon (Peg INF) in Hepatitis C (HCV) Subjects With Mild Hepatic Impairment and in HCV, Hepatitis B (HBV), Hepatitis D Infected Subjects or Alcoholic Cirrhosis With Moderate Hepatic Impairment

A Phase 1 interventional study of Tipranavir and Ritonavir in Hepatic Insufficiency, sponsored by Boehringer Ingelheim. Completed. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-01-22.

Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Registered 8 years 8 months after the study started (first participant enrolled Jan 2006, registered Sep 2014).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
36
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 13 studies in Hepatic Insufficiency by Boehringer Ingelheim — none open to participants now, none under way, none of them phase 3. Hepatic Insufficiency · Boehringer Ingelheim.

Enrollment
5th of 13
36 · median 33
Started
2006
the only one that year
Phase 1
12 of 13
none open now
Registered
8th of 13
by date

Among the 13 studies in Hepatic Insufficiency by Boehringer Ingelheim, this one is the 5th largest by enrollment, is the only one that started in 2006, is one of 12 in phase 1, and was the 8th registered.

Hepatic Insufficiency

113 studies on the registry are indexed under Hepatic Insufficiency; 15 are open to participants now.

Browse Hepatic Insufficiency studies →

Open to participants now

None of the 13 studies in Hepatic Insufficiency by Boehringer Ingelheim is open now. The open studies under Hepatic Insufficiency, anywhere →

Who these studies take

Of the 9 Hepatic Insufficiency studies recruiting now, 3 set no upper age limit and 3 stop at 75 or younger; 1 takes children under 18; 4 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 13 studies in Hepatic Insufficiency by Boehringer Ingelheim as a file.
02

Study summary

The primary objectives were:

  • To determine the effects of steady state TPV co-administered with low dose RTV on steady state PegIFN and RBV in HIV negative subjects with mild hepatic impairment (scheme A)
  • To determine the effects of steady state of pegylated interferon (PegIFN) and RBV on steady state pharmacokinetics of TPV co-administered with low dose RTV in HIV negative subjects with mild hepatic impairment (scheme A)
  • To determine the pharmacokinetics of single dose and steady state TPV/r 500/200 mg in subjects with moderate hepatic insufficiency (scheme B)
03

Conditions studied

  • Hepatic Insufficiency

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥18 and Age ≤ 75 years
  • ≥18 and BMI ≤ 29 kg/m2 (Body Mass Index) at screening visit
  • Signed and dated written prior to admission to the study in accordance with good clinical practice (GCP) and the local legislation
  • Ability to swallow multiple large capsules without difficulty
  • Serologic evidence of chronic infection by an antibody test and HCV branched DNA (bDNA) for subjects with mild hepatic impairment (Scheme A)
  • Serologic evidence of chronic hepatitis C, B and/or delta infection by an antibody test and HCV bDNA, RNA polymerase chain reaction (PCR) for subjects with moderate hepatic impairment ( B)
  • Alcoholic cirrhosis, for subjects with moderate hepatic impairment (Child Pugh B). Patients had to stop the alcohol consumption at least 1 month before the screening without any evidence of acute alcoholic hepatitis
  • Subjects HCV positive with mild hepatic insufficiency were to be on stable treatment with PegIFN and ribavirin since at least 12 weeks prior to study entry
  • Subjects with mild hepatic insufficiency were to be viral non-responders with less than a 2 log reduction in HCV RNA, compared to baseline (HCV treatment initiation) and have positive HCV RNA after 12 weeks therapy with PegIFN/RBV
  • Subjects with:

    • stable mild hepatic insufficiency treated by PegIFN and RBV
    • moderate hepatic insufficiency [Child-Pugh Class B (score 7-9)]
  • All fertile males or females, and their respective partner(s) were to be using two forms of effective during ribavirin treatment and during the 6 months after its end. All other women must agree to use an effective form of contraception during the entire duration of the study. This may include condoms, diaphragms or implants. This did not apply to those surgically sterilized or in a post menopausal state
  • Laboratory values that indicated adequate baseline organ function were required at the time of screening. All subjects with mild and moderate hepatic insufficiency should have all laboratory values less than or equal to grade 2, based on division of aids (DAIDS) Grading Scale. The following exceptions were made:

    • (ALT) and/or aspartate aminotransferase (AST) \< 3 x (ULN)
    • Alkaline Phosphatase \< 2 x ULN
    • > 10.0 g/dL
    • > 50.000 / μl And all healthy control subjects should have all laboratory values \< grade 1
  • Willingness to abstain from alcohol starting 2 days prior to administration of study drug up to the end of the study, to abstain from over counter herbal medications for the duration of the trial
  • Willingness to abstain from the following starting 14 days prior to administration of study medication up until the end of the study: Grapefruit or grapefruit juice, red wine, seville oranges (marmalade), St John's Wort or Milk Thistle
  • Willingness to abstain from the following 72 h prior to PK sampling: Garlic supplements, Methylxanthine containing drinks (coffee, tea, cola, energy drinks, chocolate, etc.)
  • Acceptable medical history, physical examination were required prior to entering the treatment phase of the trial
  • Reasonable probability for completion of the study, including dosing requirements of TPV/r and acceptance of the risk for hepatic decompensation

Exclusion criteria

Exclusion Criteria:

  • Use of any medication listed in the protocol within 30 days prior to Day 1
  • Participation in another trial with an medicine within 2 months prior to Day 1
  • (ANC) \< 750 cells/mm³ at screening
  • Serum creatine level > 1.5 times upper the limit of normal at screening
  • History of acute illness within 60 days prior to Day 1
  • Subject with mild hepatic impairment (scheme A), , , hepatitis Delta positive and/or alcoholic cirrhosis
  • Subject with moderate hepatic impairment (CPB), HIV positive
  • Subject control, HIV hepatitis positive and alcoholic cirrhosis
  • Subjects HIV positive, HBV positive and, for subjects controls positive
  • Active bleeding from oesophageal varices or other conditions consistent with active decompensated liver disease, active spontaneous bacterial peritonitis, active oesophageal variceal disease or active liver encephalopathy
  • Subjects with Class C (score > 9)
  • Alcohol abuse within 1 month prior to screening or during the study
  • Other substance abuse within 6 months prior to screening or during the study
  • Subjects with a history of any illness or allergy (including drug allergy) that, in the opinion of the investigator, might confound the results of the study or pose additional risk in administering TPV and RTV
  • Subjects who have taken (within 7 days prior to Day 1) any over-the-counter or prescription medication that, in the opinion of the investigator in consultation with the Boehringer Ingelheim France (BIF) clinical monitor, might interfere with absorption, distribution, or metabolism of the study medications
  • Known to sulphonamide class of drugs
  • Known hypersensitivity to TPV, RTV or antiretroviral drugs (marketed or experimental use as part of clinical research studies)
  • Known elevated liver enzymes in past clinical trials with any compounds
  • Inability to adhere to the protocol
  • Cautions or warnings in the RTV, PegIFN and RBV package insert which, in the opinion of the investigator, constituted grounds for subject exclusion
  • History or other evidence of severe illness, or any other conditions which would have made the patients, in the opinion of the investigator, unsuitable for the trial
  • History of any systemic antineoplasic or immunomodulatory treatment (including supraphysiologic doses of and radiation) ≤ 6 months prior to study entry or expectation that such treatment would be needed at any time during the study
  • Use of hormone replacement therapy with oestrogen-based preparations for at least 1 month prior to screening and for the duration of the study
  • Administration of antimicrobial agents within 10 days prior to Day 1 (Visit 2)
  • Subjects with evidence of hepatocellular carcinoma, or who tested positive for serum alpha foeto protein > 5μg/l or suspected tumour based on ultrasonography examination, - Patients with history of stroke, intracranial aneurysm, neurosurgery and skull traumatism within 4 weeks prior to screening
  • History of intracranial, intraocular, spinal, retroperitoneal or atraumatic intraarticular bleeding
  • Gastrointestinal hemorrhage within the past year
  • Endoscopically documented gastro-duodenal ulcer disease in the previous 30 days
  • Hemorrhagic disorder or bleeding diathesis
  • Need for anticoagulant treatment for disorders
  • Uncontrolled hypertension (systolic blood pressure (SBP) >180 mmHg and/or diastolic blood pressure (DBP) >100 mmHg)
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
36 participants (actual)

Study arms

  • Experimental
    Mild hepatic insufficiency

    Drug: Tipranavir · Drug: Ritonavir · Drug: Pegylated interferon · Drug: Ribavirin

  • Experimental
    Moderate hepatic insufficiency

    Drug: Tipranavir · Drug: Ritonavir

  • Experimental
    Healthy subjects

    Drug: Tipranavir · Drug: Ritonavir

06

What researchers measure

Primary outcomes

  1. Area under the concentration-time curve from 0 to 12 hours of ribavirin (RBV), tipranavir (TPV) and ritonavir (RTV) in the plasma (AUC0-12h)

    Time frame: Pre-dose, up to 120 hours after start of treatment

  2. Area under the concentration-time curve from 0 to 24 hours of pegylated interferon (Peg IFN) in the plasma (AUC0-24h)

    Time frame: Pre-dose, up to 120 hours after start of treatment

  3. Maximum measured concentration of RBV, Peg INF, TPV and RTV in the plasma (Cmax)

    Time frame: Pre-dose, up to 120 hours after start of treatment

  4. Measured concentration of RBV, TPV and RTV in the plasma at 12 hours (Cp12h)

    Time frame: Pre-dose, up to 120 hours after start of treatment

  5. Measured concentration of Peg INF in the plasma at 24 hours (Cp24h)

    Time frame: Pre-dose, up to 120 hours after start of treatment

  6. Area under the concentration-time curve from 0 extrapolated to infinity of TPV and RTV in the plasma (AUC0-∞)

    Time frame: Pre-dose, up to 120 hours after start of treatment

Secondary outcomes

  1. Time from dosing to the maximum concentration of the analytes in the plasma (tmax)

    Time frame: Pre-dose, up to 120 hours after start of treatment

  2. Terminal half-life of the analytes in the plasma (t1/2)

    Time frame: Pre-dose, up to 120 hours after start of treatment

  3. Apparent clearance of the analytes in the plasma after extra vascular administration (CL/F)

    Time frame: Pre-dose, up to 120 hours after start of treatment

  4. Apparent volume of distribution of the analytes in the plasma (Vz/F)

    Time frame: Pre-dose, up to 120 hours after start of treatment

  5. Number of patients with clinically significant changes in laboratory values

    Time frame: up to 3 weeks after start of treatment

  6. Number of patients with adverse events

    Time frame: Up to 7 weeks

  7. Number of patients with clinically significant changes in vital signs (seated blood pressure, pulse rate)

    Time frame: up to 3 weeks after start of treatment

  8. Number of patients with clinically significant changes from baseline in 12-lead ECG

    Time frame: 3 weeks after start of treatment

  9. Assessment of tolerability by the investigator

    verbal rating scale

    Time frame: Up to 3 weeks after start of treatment

07

Study locations

No study locations are listed for this record.

08

References and documents

Related links

Individual participant data

Plan to share: No — Clinical studies sponsored by Boehringer Ingelheim, phases I to IV, interventional and non-interventional, are in scope for sharing of the raw clinical study data and clinical study documents. Exceptions might apply, e.g. studies in products where Boehringer Ingelheim is not the license holder; studies regarding pharmaceutical formulations and associated analytical methods, and studies pertinent to pharmacokinetics using human biomaterials; studies conducted in a single center or targeting rare diseases (in case of low number of patients and therefore limitations with anonymization). For more details refer to: https://www.mystudywindow.com/msw/datatransparency

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2006 to primary completion in Oct 2008, 33 months.

Of 38 industry-sponsored phase 1 interventional studies under Hepatic Insufficiency, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 17. This study's 33 months is above that.

Counting every sponsor, half of 41 studies reached it within 8 months; a quarter within 5 and three quarters within 17.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 24, 2014
First posted
Oct 9, 2014
StartActual
Jan 1, 2006
Primary completionActual
Oct 1, 2008
Last update
Jan 22, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 22, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02259855
Responsible party
Sponsor
First posted
Oct 9, 2014
Start date
Jan 1, 2006
Primary completion
Oct 1, 2008
Last update
Jan 22, 2025

Oversight

FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Tipranavir · Ritonavir · Interferons · Ribavirin

Start the discussion